Skip to Main Content

LONDON — A major shakeup in how the benefits of medicines are assessed in Europe is looming, and developers of treatments like gene therapies are already arguing that what they see as flaws in the new system could entrench the issues they’ve had getting their products to patients.

Starting next year, there will be a new, continent-level review of a drug’s effectiveness compared to what else is on the market. It’s a wonky policy shift in the arcane world of HTA — that is, “health technology assessment,” which is when authorities review a new drug and determine what price is cost-effective — that has drugmakers big and small racing to adapt. Some have even been running dress rehearsals of the new procedures.

advertisement

“This is probably the biggest change to HTA in the last 20 to 30 years,” James Ryan, a health economist at AstraZeneca, said at a recent industry conference.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.